Efficacy and tolerability of vigabatrin in West syndrome

dc.creatorMoraes, MHP
dc.creatorMontenegro, MA
dc.creatorFranzon, RC
dc.creatorAvila, JO
dc.creatorGuerreiro, MM
dc.date2005
dc.dateJUN
dc.date2014-11-17T10:17:15Z
dc.date2015-11-26T17:25:27Z
dc.date2014-11-17T10:17:15Z
dc.date2015-11-26T17:25:27Z
dc.date.accessioned2018-03-29T00:12:41Z
dc.date.available2018-03-29T00:12:41Z
dc.identifierArquivos De Neuro-psiquiatria. Assoc Arquivos De Neuro- Psiquiatria, v. 63, n. 2B, n. 469, n. 473, 2005.
dc.identifier0004-282X
dc.identifierWOS:000230309800019
dc.identifier10.1590/S0004-282X2005000300019
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/79902
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/79902
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/79902
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1284317
dc.descriptionWest syndrome (WS) is a severe epileptic encephalopathy of childhood, characterized by spasms, developmental deterioration and hipsarhythymia. Objective: To evaluate the safety and efficacy of vigabatrin (VGB) in the treatment of WS. Method: We evaluated every patient diagnosed with WS seen at the pediatric epilepsy clinic and exposed to VGB. Patients were interviewed according to a semistructured questionnaire and we analyzed gender, age, etiology (cryptogenic or symptomatic), associated diseases, age of seizure onset, neuroimaging findings, EEG prior and after VGB, use of other antiepileptic drugs, time for seizure control, electroretinogram, visual complaints, adverse events and family history of epilepsy. Results: Twenty-three patients were evaluated, 16 boys, ages ranging from 1.25 years to 11.5 years (mean=5y3m). Sixteen (69.5%) patients were seizure free, five (22%) had partial seizure control and in two (8.5%) there was no improvement. Only one patient presented gabaergic retinopathy. Six (26%) patients presented adverse events: somnolence, aggressivity or retinopathy. Patients with seizure onset after 6 months of age presented better results after VGB introduction (p < 0.05). There was no difference in seizure control according to duration of epilepsy before VGB treatment or etiology of the seizures (p > 0.05). After VGB, no patient presented hipsarrhythymia and 50% had a normal EEG. Conclusion: Although VGB may be associated with serious adverse events such as gabaergic retinopathy, our results show that it should be considered in the treatment of WS.
dc.description63
dc.description2B
dc.description469
dc.description473
dc.languagept
dc.publisherAssoc Arquivos De Neuro- Psiquiatria
dc.publisherSao Paulo Sp
dc.publisherBrasil
dc.relationArquivos De Neuro-psiquiatria
dc.relationArq. Neuro-Psiquiatr.
dc.rightsaberto
dc.sourceWeb of Science
dc.subjectWest syndrome
dc.subjectvigabatrin
dc.subjectgabaergic retinopathy
dc.subjecthipsarhythymia
dc.subjectVisual-field Constriction
dc.subjectInfantile Spasms
dc.subjectRetinal Dysfunction
dc.subjectAntiepileptic Drugs
dc.subjectTuberous Sclerosis
dc.subjectEpilepsy
dc.subjectReversibility
dc.subjectMonotherapy
dc.subjectChildren
dc.subjectDefect
dc.titleEfficacy and tolerability of vigabatrin in West syndrome
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución